South Korea · Delayed Price · Currency is KRW Samsung Biologics Statistics
Total Valuation
KRX:207940 has a market cap or net worth of KRW 71.94 trillion. The enterprise value is 71.41 trillion.
| Market Cap | 71.94T |
| Enterprise Value | 71.41T |
Important Dates
The next estimated earnings date is Wednesday, April 29, 2026.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:207940 has 46.29 million shares outstanding.
| Current Share Class | 46.29M |
| Shares Outstanding | 46.29M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 13.26% |
| Float | 11.83M |
Valuation Ratios
The trailing PE ratio is 40.31 and the forward PE ratio is 39.66. KRX:207940's PEG ratio is 1.28.
| PE Ratio | 40.31 |
| Forward PE | 39.66 |
| PS Ratio | 15.79 |
| PB Ratio | 9.65 |
| P/TBV Ratio | 9.73 |
| P/FCF Ratio | 84.03 |
| P/OCF Ratio | 32.00 |
| PEG Ratio | 1.28 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.00, with an EV/FCF ratio of 83.41.
| EV / Earnings | 40.02 |
| EV / Sales | 15.67 |
| EV / EBITDA | 26.00 |
| EV / EBIT | 33.81 |
| EV / FCF | 83.41 |
Financial Position
The company has a current ratio of 1.74, with a Debt / Equity ratio of 0.12.
| Current Ratio | 1.74 |
| Quick Ratio | 0.88 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.34 |
| Debt / FCF | 1.08 |
| Interest Coverage | 14.64 |
Financial Efficiency
Return on equity (ROE) is 17.59% and return on invested capital (ROIC) is 17.17%.
| Return on Equity (ROE) | 17.59% |
| Return on Assets (ROA) | 9.11% |
| Return on Invested Capital (ROIC) | 17.17% |
| Return on Capital Employed (ROCE) | 24.26% |
| Weighted Average Cost of Capital (WACC) | 6.16% |
| Revenue Per Employee | 877.18M |
| Profits Per Employee | 343.47M |
| Employee Count | 5,195 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0.82 |
Taxes
In the past 12 months, KRX:207940 has paid 504.30 billion in taxes.
| Income Tax | 504.30B |
| Effective Tax Rate | 23.80% |
Stock Price Statistics
The stock price has decreased by -3.56% in the last 52 weeks. The beta is 0.33, so KRX:207940's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -3.56% |
| 50-Day Moving Average | 1,673.00 |
| 200-Day Moving Average | 1,646.00 |
| Relative Strength Index (RSI) | 44.59 |
| Average Volume (20 Days) | 42,676 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:207940 had revenue of KRW 4.56 trillion and earned 1.78 trillion in profits.
| Revenue | 4.56T |
| Gross Profit | 2.52T |
| Operating Income | 2.07T |
| Pretax Income | 2.12T |
| Net Income | 1.78T |
| EBITDA | 2.69T |
| EBIT | 2.07T |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 1.46 trillion in cash and 927.09 billion in debt, with a net cash position of 528.93 billion or 11,426.24 per share.
| Cash & Cash Equivalents | 1.46T |
| Total Debt | 927.09B |
| Net Cash | 528.93B |
| Net Cash Per Share | 11,426.24 |
| Equity (Book Value) | 7.45T |
| Book Value Per Share | 136,675.36 |
| Working Capital | 1.88T |
Cash Flow
In the last 12 months, operating cash flow was 2.25 trillion and capital expenditures -1,391.74 billion, giving a free cash flow of 856.07 billion.
| Operating Cash Flow | 2.25T |
| Capital Expenditures | -1,391.74B |
| Depreciation & Amortization | 622.41B |
| Net Borrowing | -312.07B |
| Free Cash Flow | 856.07B |
| FCF Per Share | 18,493.17 |
Margins
Gross margin is 55.23%, with operating and profit margins of 45.41% and 39.16%.
| Gross Margin | 55.23% |
| Operating Margin | 45.41% |
| Pretax Margin | 46.49% |
| Profit Margin | 39.16% |
| EBITDA Margin | 59.07% |
| EBIT Margin | 45.41% |
| FCF Margin | 18.79% |
Dividends & Yields
KRX:207940 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 2.48% |
| FCF Yield | 1.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 30, 2025. It was a reverse split with a ratio of 0.6503913.
| Last Split Date | Oct 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.6503913 |
Scores
KRX:207940 has an Altman Z-Score of 14.63 and a Piotroski F-Score of 8.
| Altman Z-Score | 14.63 |
| Piotroski F-Score | 8 |